Irving Ford on leading Adaptimmune through FDA approval and commercialisation of their T cell therapy, Tecelra.

Release Date:

We are back for Season Two of Lets Talk Quality!This week, I had the pleasure of speaking with Irving Ford, VP of Quality at Adaptimmune Therapeutics. Irving has been through the commercialisation of four cell therapy products, most recently leading Adaptimmune through the BLA and FDA approval of their engineered T cell for solid tumour, Tecelra. Irving talks about his journey from starting out his career as a Microbiologist before making his transition into the pharmaceutical industry. He started in a generics company which exposed him to a variety of product types. He worked his way up into leadership positions, across multiple different aspects of quality, to get to where he is now. TakeawaysThe benefit of working in multiple aspects of quality in your early careerDeveloping trust and building leadership capabilitiesDeveloping different generations of people Putting yourself out of your comfort zone in your careerKey ingredients for moving from clinical to commercial operations in cell therapyUnlearning everything you've learnt when working in cell therapyTraining for mindset and continuous developmentManaging stress, workload and your emotionsIrving's values, views on legacy, inspiration, and advice for future leaders!Chapters00:00 Introduction and Overview of Irving Ford03:00 Transitioning from Clinical to Commercial Operations11:33 Building Strong Relationships and Creating a Positive Work Culture19:24 Challenges and Real-Time Decision Making in Cell Therapy25:30 Personal Values and Leaving a Legacy32:18 Advice for Future Quality LeadersHuge thank you to Irving for giving us his time!

Irving Ford on leading Adaptimmune through FDA approval and commercialisation of their T cell therapy, Tecelra.

Title
Irving Ford on leading Adaptimmune through FDA approval and commercialisation of their T cell therapy, Tecelra.
Copyright
Release Date

flashback